Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC) MedDRA version: 22.1 Level: LLT Classification code 10061229 Term: Lung infection System Organ Class: 100000004862
Conditions
Interventions
Product Name: Amikacin liposome inhalation suspension (ALIS)
Pharmaceutical Form: Inhalation solution
INN or Proposed INN: Amikacin sulfate (1:2)
Other descriptive name: AMIKACIN SULFATE PH. EUR.
Conc
Sponsors
Insmed Incorporated
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Subjects must satisfy all of the following criteria to be included in the study: 1. Male or female, = 18 years of age (20 years or older in Japan) 2. Current diagnosis of MAC lung infection (initial, second, or third infection event). MAC or mixed infection with MAC as the dominant species allowed, with MAC as the intended organism for treatment 3. Positive sputum culture for MAC within 6 months prior to Screening 4. Positive sputum culture for MAC at Screening 5. A high-resolution chest computed tomography (CT) scan or chest CT scan with contrast, read locally, within 6 months prior to Screening. Subjects who do not have a chest CT scan within 6 months prior to Screening will be required to obtain a high-resolution chest CT scan or chest CT scan with contrast, read locally, during Screening. 6. In the Investigator’s opinion, documented respiratory signs/symptoms at Screening that are attributable to the current MAC lung infection 7. An average QOL-B respiratory domain score of = 85 based on scores at Screening and on the day of enrollment prior to randomization 8. In the Investigator’s opinion, underlying lung disease (eg, chronic obstructive pulmonary disease [COPD], bronchiectasis) have been managed according to best local standard of care, and on stable maintenance therapy for a minimum of 4 weeks prior to randomization 9. Adherence to a predefined multidrug antimycobacterial regimen during the study 10. Ability to produce (spontaneously or with induction) approximately 2 mL of sputum for mycobacteriology at Screening 11. Women of child-bearing potential (WOCBP) agree to practice an acceptable method of birth control (eg, true abstinence [refraining from heterosexual intercourse during the entire study], copper intrauterine device [IUD], hormonal methods (levonorgestrel-releasing intrauterine system, progestogen implant, combined oral contraceptive pill [combined with barrier method] or double barrier method plus a spermicidal agent, exclusive homosexual relationship, or sole male partner who has undergone surgical sterilization with confirmation of azoospermia at least 3 months post procedure) while participating in the study. 12. Provide signed informed consent prior to administration of study drug or performing any study related procedure 13. Be able to comply with study drug use, study visits, and study procedures as defined by the protocol Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 80 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 20
Exclusion criteria
Exclusion criteria: Subjects who meet any of the following criteria will be disqualified from entering the study: 1. Diagnosis of cystic fibrosis (CF) 2. History of 3 or more prior MAC lung infections 3. Received any mycobacterial antibiotic treatment for current MAC lung infection 4. Refractory MAC lung infection, defined as having positive MAC cultures while being treated with a multidrug mycobacterial antibiotic treatment regimen for a minimum of 6 consecutive months and no documented successful treatment, defined as negative sputum culture for MAC and cessation of treatment 5. Relapse of prior MAC lung infection, defined as positive sputum culture for MAC = 6 months of cessation of prior successful treatment 6. MAC isolate with MIC for liposomal amikacin = 128 µg/mL at Screening 7. Evidence of any pulmonary cavity = 2 cm in diameter, as determined by chest CT scan, read locally, within 6 months prior to Screening 8. Radiographic finding of new lobar consolidation, atelectasis, significant pleural effusion, or pneumothorax during routine clinical care within 2 months prior to Screening 9. Active pulmonary malignancy (primary or metastatic) or any malignancy requiring chemotherapy or radiation therapy within 1 year prior to Screening or anticipated during the study 10. Active pulmonary tuberculosis requiring treatment during Screening 11. Hospitalization for underlying lung disease during Screening 12. Acute pulmonary exacerbation (eg, COPD or bronchiectasis) requiring treatment with antibiotics, or corticosteroids (IV or oral), within 4 weeks prior to and during Screening 13. Predicted forced expiratory volume in 1 second (FEV1) 2 times ULN at Screening 27. Current alcohol, medication, or illicit drug abuse 28. Any condition that, in the opinion of the Investigator, interferes with ability to safely complete the study or adhere to study requirements
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To generate evidence demonstrating the domain specification (via modern psychometric methods), reliability, validity, and responsiveness (within-subject meaningful change) of the patient-reported outcome (PRO) endpoints.;Secondary Objective: To evaluate the effect of each treatment arm: 1. Culture conversion by end of treatment (EOT) (M6) 2. Patient-reported respiratory symptoms at 1 month off treatment (M7) 3. Patient-reported fatigue symptoms at 1 month off treatment (M7) 4. Time to culture conversion 5. Time to first negative culture 6. MAC isolates with amikacin minimum inhibitory concentration (MIC) = 128 µg/mL 7. Recurrence of MAC (relapse) 8. Recurrence of MAC (new infection) 9. To evaluate the safety and tolerability of ALIS +AZI+ETH;Timepoint(s) of evaluation of this end point: 1) Baseline 2) Between screening and baseline and 3) Between Baseline and End of Study (EOS) (Month 7).;Primary end point(s): Findings on psychometric validation optimized and reported for: 1) Cross-sectional validation (modern psychometrics, internal consistency, concurrent validity, and known-groups validity) at Baseline. 2) Test-retest reliability between Screening and Baseline among subjects reporting no change on Patient Global Impression of Severity (PGI-S) between Screening and Baseline. PGI-S anchors will be PRO specific, with a respiratory and fatigue PGI-S applied to the Quality of Life – Bronchiectasis (QOL-B) respiratory domain and Patient-Reported Outcome Measurement Information System – Fatigue-Short Form 7a (PROMIS F-SF 7a), respectively. 3) Within-subject meaningful change estimated via anchor-based methods and validated via empirical cumulative distribution functions (eCDFs) and probability density functions (ePDFs) between Baseline and End of Study (EOS) (Month 7). | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Proportion of subjects achieving culture conversion by EOT (Month 6) (negative cultures for MAC at Month 5 and Month 6) Change from Baseline to 1 month off treatment (Month 7) in respiratory symptoms (as assessed by QOL-B) Change from Baseline to 1 month off treatment (Month 7) in fatigue symptoms (as assessed by PROMIS F-SF 7a) Time to culture conversion (2 consecutive negative cultures of baseline to EOT assessments) Time to first negative culture (of baseline to EOT assessments) Proportion of subjects who develop a MAC isolate with amikacin MIC = 128 µg/mL at any timepoint during the study Proportion of subjects who achieved culture conversion and subsequently have a MAC positive culture that is the same species and genome as cultured at Screening/Baseline. Proportion of subjects who achieved culture conversion and subsequently have a MAC positive culture that is different than cultured at Screening/Baseline (different species or same species but different genome). Incidence and severity of treatment-emergent adverse events (TEAEs) and other safety variables (eg, vital signs, physical examination, clinical laboratory values) from Baseline through the EOS.;Timepoint(s) of evaluation of this end point: From Baseline to 1 month off treatment (Month 7). Month 5 and 6 | — |
Countries
Argentina, Australia, Austria, Belgium, Canada, Chile, Denmark, France, Greece, Hungary, Israel, Japan, Korea, Republic of, Netherlands, New Zealand, Poland, Portugal, Spain, Taiwan, Turkey, United Kingdom, United States
Contacts
Public ContactSr Director Regulatory Affairs EMEA
Insmed Switzerland GmbH
Outcome results
None listed